3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
5
Recruiting
2
Active not recruiting
2
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
8
Neuroendocrine Tumors
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Disease
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Vasculitis
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Smoking Cessation
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Pancreatic Cystic Neoplasms
1
Osteomyelitis
1
Nose Neoplasms
1
Neurodegenerative Diseases
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Multiple Pulmonary Nodules
1
Interventions
Trastuzumab
350
Paclitaxel
334
Cyclophosphamide
315
Docetaxel
291
Capecitabine
181
Doxorubicin
180
Letrozole
165
Tamoxifen
145
Bevacizumab
124
Fulvestrant
118
Carboplatin
118
exemestane
111
Lapatinib
111
Anastrozole
111
Radiotherapy
105
Epirubicin
104
Gemcitabine
97
palbociclib
83
Exercise
78
Vinorelbine
77
Fluorouracil
77
Surveys and Questionnaires
71
pertuzumab
67
Filgrastim
64
Albumin-Bound Paclitaxel
64
eribulin
55
Magnetic Resonance Spectroscopy
55
Everolimus
52
Blood Specimen Collection
51
Zoledronic Acid
50
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Breast Neoplasms
×
Positron-Emission Tomography
×
Clear all
NCT02437539
2015-08-24
uPAR-PET
Rigshospitalet, Denmark
Phase 1
Completed
10 enrolled